Mankind Pharma
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Mankind Pharma is strategically transitioning towards a higher-value business model, with a focus on chronic and specialty therapeutics, which now represent approximately 39% of its domestic revenue. This shift is supported by management's emphasis on integrating Bharat Serums and Vaccines (BSV), which is expected to enhance the company's capabilities in complex biologics and women's health. Despite facing margin pressures from rising input costs and a competitive landscape, Mankind's commitment to a therapy-based approach over price competition positions it well for sustainable growth. Vista's financial outlook anticipates stable margins and a revenue growth trajectory, bolstered by the company's strategic initiatives and a robust consumer healthcare segment. The expected deleveraging of the balance sheet by FY28 is projected to further enhance earnings growth. However, execution risks related to the BSV integration and broader market volatility remain key watchpoints. Over the next 12-24 months, Mankind's growth will be influenced by its ability to scale the BSV business, increase hospital penetration, and navigate the evolving regulatory landscape. Overall, the company is poised for double-digit growth, with a target price reflecting a 23.7% upside from current levels
Why We Like This Stock
- Transition towards chronic and specialty therapeutics is expected to drive revenue growth
- Successful integration of BSV is anticipated to enhance product offerings and market position
- Stable margins and a focus on deleveraging will support long-term earnings growth
Things To Watch Out For
- Execution risks associated with the BSV integration could impact growth timelines
- Rising input costs may pressure margins across the sector
- Increased competition in the biosimilars space could affect market share
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 10,260 | 12,207 | 14,278 | 14,835 | 16,706 |
| Profit Before Tax (Cr.) | 2,264 | 2,194 | 2,463 | 2,701 | 3,142 |
| PBT Margin | 22.1% | 18.0% | 17.3% | 18.2% | 18.8% |
| Net Profit (Cr.) | 1,801 | 1,670 | 1,847 | 2,024 | 2,323 |
| Earnings Per Share | 42.9 | 39.9 | 44.1 | 48.3 | 56.2 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Kotak Securities | ▲ Buy | 3,000 | 22-Sep-2026 |
| Elara Capital | ► Accumulate | 2,616 | 27-Aug-2026 |
| HDFC Securities | ► Add | 2,850 | 03-Aug-2026 |
| JPMorgan | ► Neutral | 2,700 | 03-Aug-2026 |
| Macguire | ▼ Underperform | 2,080 | 31-Jul-2026 |
| Motilal Oswal | ▲ Buy | 2,975 | 31-Jul-2026 |
| Jeffries | ▲ Buy | 3,000 | 08-Jul-2026 |
| Geojit Financials | ► Add | 2,660 | 16-Jun-2026 |
| Bernstein | ▼ Reduce | 2,057 | 22-May-2026 |
| Morgan Stanley | ▲ Overweight | 2,735 | 21-May-2026 |
Company Overview
Show Company Profile
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, urology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory, and other diseases. It also provides consumer healthcare products, such as condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. In addition, the company engages in the trading of pharmaceutical and health care products; manufacture of packing materials, ayurvedic products, and consumer goods; real estate, leasing, and hospitality businesses; trading of agricultural and pet food products; and provision of IT services. It offers its products under the Manforce, Moxi Kind-Cv, AmLokind-At, Unwanted-Kit, Prega News, Dydroboon, Telmikind-Am, Gudcef, Glimestar-M, Candi Force, Nurokind-Gold, Telmikind-H, Telmikind, Nurokind-Lc, Nurokind Plus-Rf, Vomikind, Cefakind, Glizid-M, Monticope, and Gudcef-Cv brand names. Mankind Pharma Limited was incorporated in 1991 and is based in New Delhi, India.